Literature DB >> 11417488

An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners.

J L Huret, P Dessen, A Bernheim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11417488     DOI： 10.1038/sj.leu.2402135

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  29 in total

1.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

2.  Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Authors:  Fabiana Perna; Michel Sadelain
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

Review 3.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

Review 4.  Therapeutic opportunities and targets in childhood leukemia.

Authors:  Anthony M Ford; Angel Martínez-Ramírez
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

5.  Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Authors:  Emma C Collins; Alexandre Appert; Linda Ariza-McNaughton; Richard Pannell; Yoshihiro Yamada; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

6.  Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.

Authors:  Akihiko Yokoyama; Zhong Wang; Joanna Wysocka; Mrinmoy Sanyal; Deborah J Aufiero; Issay Kitabayashi; Winship Herr; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  Loss of Dnmt3b accelerates MLL-AF9 leukemia progression.

Authors:  Y Zheng; H Zhang; Y Wang; X Li; P Lu; F Dong; Y Pang; S Ma; H Cheng; S Hao; F Tang; W Yuan; X Zhang; T Cheng
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

8.  Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.

Authors:  Venita Gresham Watson; Katherine M Drake; Yu Peng; Andrew D Napper
Journal:  Assay Drug Dev Technol       Date:  2013-05       Impact factor: 1.738

9.  The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.

Authors:  Yousaf A Mian; Nancy J Zeleznik-Le
Journal:  Leuk Res       Date:  2016-04-16       Impact factor: 3.156

10.  MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.

Authors:  M C Stubbs; Y M Kim; A V Krivtsov; R D Wright; Z Feng; J Agarwal; A L Kung; S A Armstrong
Journal:  Leukemia       Date:  2007-09-13       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.